Adaptimmune: Transfer of PRAME and NY-ESO Target Programs from GSK

 

• Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –

• GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2023 –

• Adaptimmune will continue to prioritize and focus on its lead MAGE-A4 franchise while determining the optimal development path for complementary PRAME and NY-ESO assets –

https://finance.yahoo.com/news/adaptimmune-enhances-pipeline-wholly-owned-120000868.html